CNBC October 11, 2024
Jessica Dickler

Key Points

– About 165 million Americans rely on employer-sponsored health insurance, and yet workers may still not get the coverage they want — particularly when it comes to drugs such as Wegovy and Ozempic.

– Currently, less than half of employers cover the expensive weight-loss medications.

– Even those that do cover them have guardrails in place that restrict access.

About 165 million Americans rely on employer-sponsored health insurance, and yet workers may still not get the coverage they want — particularly when it comes to drugs such as Novo Nordisk’s weight-loss drug Wegovy and diabetes drug Ozempic.

About 1 in 3 employees are looking for more resources to combat obesity, according to a recent report by consulting firm...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Employer, Healthcare System, Patient / Consumer, Pharma / Biotech, Pricing / Spending
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article